RILUTEK DIN 02242763
Health Canada record
| Active ingredient(s) | RILUZOLE 50 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N07XX02 RILUZOLE |
| Original market date | 26-Oct-2000 |
| Current status date | 08-Jan-2007 |
| Source | Health Canada DPD |
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RILUZOLE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02352583 | APO-RILUZOLE | APOTEX INC | Tablet | RILUZOLE 50 MG | Marketed |
| 02390299 | MYLAN-RILUZOLE | MYLAN PHARMACEUTICALS ULC | Tablet | RILUZOLE 50 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 7839 | 2006-03-21 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 1442 | 2000-08-30 | New Drug Submission (NDS) |
International API supply for RILUZOLE
6 active FDA Drug Master Files.
Request a quote for RILUTEK